[USPRwire, Tue Apr 20 2010] Advances in particle engineering, encapsulation chemistry, surface property optimization and solubility enhancement are enabling the creation of tailorable formulations for both new and existing compounds. More than three dozen companies now offer the equivalent of a formulation ‘tool kit’ that employs proprietary methods for improving the properties of candidate drugs. . Much of the current focus in formulation science is concerned with processes that can improve the solubility of APIs. The importance of solubilization technologies is also underscored by the capability they bestow on formulators attempting to re-formulate approved drugs approaching the end of their patent life.
More than ever before, drug formulation technology is now seen as a key enabler of new prescription products. As large-molecule therapeutics increase both in number and as a percentage of all drug discoveries, the appeal of drug formulation technologies – particularly those that can improve solubility - will escalate.
The importance of proprietary formulation technologies is further underscored by the capability they bestow on formulators attempting to modify approved drugs approaching the end of their patent life. The decision to rely on these new development tools can have a potential downside, however. While their potential is obvious, the use of third party proprietary formulation technologies can result in complexities that can percolate throughout the organization.
Drug formulation technology companies are working with drug developers at pharmaceutical companies to help define the prescription formulations that will enter preclinical development and the clinical trial pipeline in the coming months and years. New formulation capabilities will expand the number of new NCEs that can be formulated to meet pharmacochemical thresholds.
A new report examines the implications of these trends on pharmaceutical drug discovery and development. Drug Solubility – Solubility Technology Platforms, Players and Prospects contains analysis and evaluations of branded drug solubility technologies, an assessment of market and technology factors, market data and forecasts to 2013, and profiles of drug formulation technology companies.
More information is available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org
Source: Greystone Associates
Company: Greystone Associates
Contact Name:
Mark Smith
Contact Email:
mksmith@greystoneassociates.org
Contact Phone:
603-595-4340
Related website
